British Journal of Radiology (2006) 79, 510-517
© 2006 British Institute of Radiology
doi: 10.1259/bjr/83726649
Clinical and cellular ionizing radiation sensitivity in a patient with xeroderma pigmentosum
C F Arlett, PhD1,
P N Plowman, MD, FRCP, FRCR2,
P B Rogers, MB BS, MRCP, FRCR2,
C N Parris, PhD3,
F Abbaszadeh, MSc3,
M H L Green, PhD4,
T J McMillan, PhD5,6,
C Bush, BSc6,
N Foray, PhD7 and
A R Lehmann, PhD1
1 Genome Damage & Stability Centre, University of Sussex, Falmer, Brighton BN1 9RQ, , 2 Radiotherapy/Clinical Oncology, St Bartholomew's Hospital, 25 Bartholomew Close, West Smithfield, London EC1A 7BE, , 3 Division of Biosciences, School of Health Sciences and Social Care, Brunel University, Kingston Lane, Uxbridge, Middlesex UP8 3PH, , 4 School of Pharmacy and Biomolecular Sciences, University of Brighton, Cockcroft Building, Lewes Road, Brighton BN2 4GJ, , 5 Institute of Environmental and Natural Sciences, Faraday Building, Lancaster University, Lancaster LA1 4YA, , 6 The Institute of Cancer Research, Royal Cancer Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK, , 7 INSERM U647, ID17, European Synchrotron Research Facility, Rue Jules Horowitz, BP220 38043 Grenoble, France,

View larger version (136K):
[in a new window]
|
Figure 1. The irradiated scalp portal. The irradiated skin remained depilated and became frankly ulcerated and necrotic in the operation wound site.
|
|

View larger version (71K):
[in a new window]
|
Figure 2. CT brain scan demonstrating widespread hemispheric oedema beneath the irradiated portal. Noteworthy is the widespread extent of the oedema throughout the hemisphere, not withstanding the restricted portal size, the moderate prescription dose(38 Gy) and the low energy electron portal (6 MEV) that had to penetrate bone first. It was this unrelenting cerebral oedema, emanating from radio necrosis of brain under the radiation portal, that caused death.
|
|

View larger version (20K):
[in a new window]
|
Figure 4. Ionizing radiation clonal survival of XP14BR fibroblasts. Key as forFigure 3 : Additional XP line; XP233VA; Ataxia telangiectasia fibroblast lines; AT1BR; AT2BR. Means ± standard error based on numbers of experiments as follows: XP14BR.1, 1; XP14BR.2, 6; 1BR.3, 58; 142BR, 8; 250BR, 4; 251BR, 13; XP23BE, 2; XP233VA, 2; AT1BR, 5; AT2BR, 3.
|
|

View larger version (63K):
[in a new window]
|
Figure 8. Immunoblotting for the C-terminal end of the XPC protein. Lanes 1 and 2, T921A, T943A (transfectants); lane 3, XP14BRneo17 (recipient); lane 4, MRC5V1 (control); lanes 5 and 6, T941B and T948B (transfectants). Upper panel, 20 s exposure, lower panel, 5 min exposure.
|
|
Copyright © 2006 by the British Institute of Radiology.